Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Next Previous
Search
Trial Profile

A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciltacabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms CARTITUDE-1
  • Sponsors Janssen Pharmaceuticals; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson Innovative Medicine

    • Most Recent Events

    • 12 Dec 2023 3 year follow up results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results (N=332) of pooled analysis ( CARTITUDE-1, CARTITUDE-2 (Cohorts A, B, and C), and CARTITUDE-4) assessing the clinical experience with presentation and management of cranial neuropathy (CNP) in pts treated with cilta-cel in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and CARTITUDE-4 studies were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 12 Dec 2023 Results of pooled analysis after applying the KarMMa-3 inclusion and exclusion criteria to the CARTITUDE-1 and CARTITUDE-4 contextualizing the efficacy of cilta-cel compared to other available CAR-Ts for multiple myeloma, presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top